This document is a quick and concise evidence-based summary to provide additional information, instruction, or guidance to complement a treatment protocol or clinical resource document. 

Early stage Hodgkin lymphoma (stage l and ll) is divided into favourable and unfavourable characteristics. The tables below indicate the variations in criteria for defining risk groups according to the various trial groups. Treatment of choice should match the risk stratification by trial group. 

Table 1r

Risk stratification of early-stage Hodgkin lymphoma, by research group

© The Lancet 2012

Table 2 r

© NEJM 2010

While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/207

19 Apr 2024